SLRX Salarius Pharmaceuticals Inc
Price (delayed)
$0.7265
Market cap
$1.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.79
Enterprise value
-$944,389
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment
Highlights
The EPS has soared by 81% YoY and by 10% from the previous quarter
The debt has contracted by 33% from the previous quarter and by 23% YoY
SLRX's net income has surged by 56% year-on-year but it is down by 12% since the previous quarter
SLRX's equity has shrunk by 71% YoY and by 48% QoQ
The quick ratio has dropped by 65% year-on-year and by 54% since the previous quarter
Key stats
What are the main financial stats of SLRX
Market
Valuations
Earnings
Shares outstanding
1.75M
Market cap
$1.27M
Enterprise value
-$944,389
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$5.73M
Net income
-$5.58M
EBIT
-$5.58M
EBITDA
-$5.57M
Free cash flow
-$4.53M
Per share
Balance sheet
Liquidity
EPS
-$5.79
EPS diluted
-$5.79
Free cash flow per share
-$4.7
Book value per share
$1.05
Revenue per share
$0
TBVPS
$3.14
Total assets
$3.02M
Total liabilities
$1.51M
Debt
$221,866
Equity
$1.51M
Working capital
$1.48M
Debt to equity
0.15
Current ratio
1.98
Quick ratio
1.61
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-145.6%
Return on equity
-213.2%
Return on invested capital
N/A
Return on capital employed
-368.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLRX stock price
How has the Salarius Pharmaceuticals stock price performed over time
Intraday
3.79%
1 week
-15.24%
1 month
-32.73%
1 year
-79.93%
YTD
-60.52%
QTD
-3.65%
Financial performance
How have Salarius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$5.73M
Net income
-$5.58M
Gross margin
N/A
Net margin
N/A
SLRX's net income has surged by 56% year-on-year but it is down by 12% since the previous quarter
The operating income has soared by 56% YoY but it fell by 10% QoQ
Growth
What is Salarius Pharmaceuticals's growth rate over time
Valuation
What is Salarius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 81% YoY and by 10% from the previous quarter
SLRX's equity has shrunk by 71% YoY and by 48% QoQ
The P/B is 26% lower than the last 4 quarters average of 0.9 and 16% lower than the 5-year quarterly average of 0.8
Efficiency
How efficient is Salarius Pharmaceuticals business performance
SLRX's ROE has plunged by 52% from the previous quarter and by 8% YoY
The ROA is down by 38% QoQ and by 8% YoY
Dividends
What is SLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLRX.
Financial health
How did Salarius Pharmaceuticals financials performed over time
Salarius Pharmaceuticals's total assets is 100% higher than its total liabilities
The quick ratio has dropped by 65% year-on-year and by 54% since the previous quarter
The company's total liabilities has surged by 62% QoQ and by 16% YoY
The debt is 85% less than the equity
SLRX's debt to equity has soared by 200% YoY and by 36% from the previous quarter
SLRX's equity has shrunk by 71% YoY and by 48% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.